lymphoma

[PLoS Pathogens] Both in vitro and in vivo Treg migration was effectively blocked by a novel, small molecule antagonist of CCR4, CCR4-351.

[Bone Marrow Transplantation] Clonal hematopoiesis was associated with increasing age and with a factor 6 increase in the risk of developing therapy-related myeloid neoplasms following autologous stem cell transplantation.

[Bioengineered] Scientist found ZNF267 was significantly upregulated in diffuse large B-cell lymphoma and predicted a poor survival outcome based on the bioinformatics analysis.

[Rafael Pharmaceuticals, Inc. (Globe Newswire, Inc.)] Rafael Pharmaceuticals, Inc. announced the completion of the first cohort of dose escalation with no DLT in the APOLLO 613 Phase I/II clinical trial of devimistat in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma.

[Nature Communications] Investigators developed a B cell-activating factor (BAFF) ligand-based CAR and generated BAFF CAR-T cells using a non-viral gene delivery method.

[Daiichi Sankyo Company, Limited] Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T cell leukemia/lymphoma.